A network for collaborative cancer research in Ontario
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 3 sites (Kingston, Ontario and 2 other locations) |
| Trial ID | NCT05403177 on ClinicalTrials.gov |
What this trial studies
The Marathon of Hope Cancer Centres Network (MOHCCN) aims to enhance cancer treatment through precision medicine by leveraging genomics and artificial intelligence. This observational study will enroll approximately 15,000 participants in its initial phase, with a long-term goal of reaching 100,000 participants over ten years. By analyzing individual variability in DNA, environment, and lifestyle, the study seeks to ensure that patients receive the most effective treatments tailored to their specific cancer types. The research will focus on various cancers, including breast, colorectal, pancreas, kidney, and prostate cancers.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed blood or solid tumor malignancies who can provide the necessary data and biospecimens.
Not a fit: Patients without a confirmed malignancy or those unable to provide the required data and biospecimens may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective cancer treatments for patients.
How similar studies have performed: Other studies utilizing precision medicine and collaborative networks have shown promise, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: 1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1) 2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization 3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling. 4. Participating patients must agree to share their anonymized clinical and genomic data Exclusion Criteria: None.
Where this trial is running
Kingston, Ontario and 2 other locations
- Kingston Health Sciences Centre — Kingston, Ontario, Canada (Recruiting)
- Ottawa Health Research Institute — Ottawa, Ontario, Canada (Not_yet_recruiting)
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Lillian Siu, MD — University Health Network, Toronto
- Study coordinator: PM2C Central Office
- Email: MOHCCN@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.